NEW YORK (GenomeWeb News) – The drug discovery company Chemizon has struck a strategic partnership with the clinical research company Crown Biosciences to offer a number of drug research capabilities, including proteomics and biomarker services, Chemizon said today.
Chemizon, which is a division of Optomagic, also said it has made an investment in CrownBio of an undisclosed amount through a private equity fund.
The partnership will offer products and services in areas such as protein cloning and expression, protein purification, biomarker discovery and development, and X-ray crystallography, among others.
CrownBio has headquarters in Silicon Valley as well as research centers in Beijing and Indianapolis.
“With the cost of developing breakthrough therapeutics continuing to climb, we are poised to take advantage of the shift of high-value discovery research to Asia, by providing a state-of-the-art scientific platform to our collaborators,” Crown Biosience CEO Alex Wu said in a statement.